Patent intelligence · US
US 20260051027
GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES
GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES
Patent details — US 20260051027
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 19, 2026
- Expiration
- Feb 14, 2046
- Applicant
- BAYER AG [DE]
- CPC classes
- A61K 49/ 00 A I, A61K/490002
Quick answer
US 20260051027 (GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES) is held by BAYER AG [DE]. Status: granted. Granted Feb 19, 2026. Expires Feb 14, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 49/ 00 A I, A61K/490002
More from BAYER AG [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2026112109
TECHNOLOGIE DE PLATEFORME DE GRANULATION PAR VOIE HUMIDE POUR FABRIQUER DES COMPRIMÉS/ARTICLES À MÂCHER MOUS
granted -
WO 2026106858
FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES
granted -
EP 4741400
MULTIMERE MANGANKONTRASTMITTEL
granted -
WO 2026068294
PROCESSUS DE NANOENSEMENCEMENT AMÉLIORÉ
granted -
WO 2026047020
FORMES CRISTALLINES D'INHIBITEURS DE HER2/MUTEGFR ET LEUR PROCÉDÉ DE PRÉPARATION
granted -
WO 2026047022
FORME POSOLOGIQUE PHARMACEUTIQUE SOLIDE ET STABLE COMPRENANT UNE FORME CRISTALLINE D'UN INHIBITEUR DE HER2/MUTEGFR ET SA MÉTHODE DE PRÉPARATION
granted -
WO 2026032865
SEL D'UN INHIBITEUR DE SOS-1
granted
Frequently asked questions
What is US patent 20260051027?
US 20260051027 (GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES) is held by BAYER AG [DE]. Status: granted. Granted Feb 19, 2026. Expires Feb 14, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 20260051027?
BAYER AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 20260051027 expire?
Our index shows an expiration date of Feb 14, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.